Phospholipase C beta 2 (PLCB2)

Phospholipase C beta 2 (PLCB2) is a member of the phosphoinositide-specific phospholipase C family of enzymes that catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two key second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). This reaction serves as a critical point in signal transduction for numerous G protein-coupled receptor (GPCR)-mediated pathways, leading to intracellular calcium mobilization and activation of protein kinase C. PLCB2 is primarily activated by G protein alpha subunits (Gαq, Gα11) and by Gβγ subunits, and plays fundamental roles in cardiovascular, neuronal, and immune cell signaling, as well as in taste transduction and platelet activation. Deregulation of PLCB2 activity has been implicated in cancer, inflammation, familial hepatic adenomas, and Charcot-Marie-Tooth disease, highlighting its emerging significance as a therapeutic target and biomarker in disease. No currently approved drugs specifically target PLCB2, but its key role in essential signaling pathways makes it a subject of ongoing research.

Other names

1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-2PLC-beta-2phosphoinositide phospholipase C-beta-2FLJ38135Phospholipase C-beta-2PLC-β-2AI550384B230205M18B230205M18RikB230399N12

Inhibitors would block the generation of IP3 and DAG by suppressing phosphatidylinositol 4,5-bisphosphate hydrolysis, thus modulating calcium signaling and downstream protein kinase C activation